Table 1.
Table 1a. Sample Characteristics with Comparisons of Depression statusa
| Depressive symptoms (n = 54) | No depressive symptoms (n = 300) | |
|---|---|---|
| Age, y (SD) | 71.37 (5.40) | 72.48 (5.47) |
| Education, y (SD) | 15.00 (2.73) | 15.75 (2.80) |
| MMSE, scoreb(SD) | 28.78 (1.53) | 28.86 (1.36) |
| GDS (SD) | 3.06 (2.33)* | 0.73 (0.96) |
| Sex, % female | 70.4* | 50.3 |
| APOE ε4, % positive | 31.5 | 35.3 |
| Table 1b. Sample Characteristics with Comparisons of Preclinical AD status | ||||
|---|---|---|---|---|
| Preclinical AD statusc | Stage 2 or 3 Preclinical AD statusd | |||
| Biomarker positive(n = 107) | Biomarker negative (n=249) | Biomarker positive(n = 47) | Biomarker negative (n=309) | |
| Age, y (SD) | 74.94 (6.49)* | 72.09 (5.49) | 75.69 (5.95)* | 72.53 (5.84) |
| Education, y (SD) | 15.93 (3.09) | 15.47 (2.83) | 14.91 (2.68) | 15.67 (2.85) |
| MMSE, scoreb (SD) | 28.61 (1.50)* | 29.07 (1.19) | 28.57 (1.61)* | 28.95 (1.28) |
| GDS (SD) | 0.99 (1.23) | 0.96 (1.40) | 1.04 (1.20) | 1.03 (1.49) |
| Sex, % female | 49.5 | 55.8 | 51.1 | 57.0 |
| APOE ε4, % positive | 49.5* | 27.3 | 53.2* | 31.5 |
a
Two participants were not included due to missing information.
b
Scored 1–30; 30 is a perfect score.
c
Preclinical AD here represents an abnormal biomarker result from PET-PiB neuroimaging, or CSF assay (using only abnormal Aβ1–42 as a cutoff), or both, in cognitively normal persons.
d
Stage 2 or 3 Preclinical AD represents both abnormal Aβ1–42 and tau levels
*
P < 0.01, compared to the group with no depressive symptoms (table 1a) or no preclinical AD (table 1b)
Abbreviations: MMSE, Mini-Mental Status Exam; APOE ε4, ApolipoproteinE ε4.